603. Feldan Shuttle - Advanced Protein Delivery Technology for Cell Therapy
Bibliographic record
Abstract
Methods for maximizing the therapeutic value of human cells often involve the transfer of genetic material and use of viruses, both raising important safety and economical concerns. One promising solution to improve cell therapy processes consists on the direct delivery of active proteins into human cells. Regenerative medicine studies established powerful proofs of concept using delivery of transcription factors for cell reprogramming and differentiation; however, the lack of efficiency of current protein delivery methods slowed down the transfer of these methods toward human clinical researches. In the last years, the CRISPR/Cas9 revolution brought forward the possibility of using diverse transfection approaches to deliver Cas9 protein complexed with guide RNA, a method yielding interesting results with cationic lipid agents and electroporation systems. In a human therapy context, lipidic agents are generally not suitable because of their high cellular toxicity. As for electroporation, few systems have been approved for cell therapy; in addition, this process represents a serious concern because of its high cost, inconsistency, associated cell mortality and the fact that some cells are simply refractory to electroporation. In all, these characteristics accentuate the need for a protein delivery process suitable for human cell therapy. In order to efficiently use transcription factors, Cas9 or any other intracellular proteins in cell therapy, Feldan Therapeutics is developing a protein delivery agent, the Feldan Shuttle, explicitly designed for cell therapy. Feldan Shuttle is entirely protein-based, thus allowing cells to naturally degrade it and the delivered protein after their active use. With this novel method, Feldan Therapeutics successfully delivered fluorescent proteins as well as functionally active transcription factors and Cas9/RNA complex with high efficiency and low toxicity into multiple cell lines and human primary cells. With this new technology, Feldan Therapeutics offers an innovative method designed to efficiently and safely deliver native proteins for cell therapy applications.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".